Form 8-K · Current Report · Filed 2025-06-20
Cidara Therapeutics Increases Authorized Share Count
Cidara Therapeutics, Inc. announced that its stockholders approved an amendment to increase the authorized number of shares of Common Stock from 50,000,000 shares to 100,000,000 shares at the 2025 Annual Meeting of Stockholders. The meeting also saw approval of amendments to the 2024 Equity Incentive Plan and the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers.
- Filer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Accession
- 0001610618-25-000072
- CIK
- 0001610618
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Amendments to Articles of Incorporation or Bylaws
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$21.31
Next session
+110.9%
Since filing
+938.9%
Latest close
$221.38
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CDTX reporting the same item, with the next session's move:
Exhibits (2)
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Never miss another CDTX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.